{"id":3925,"date":"2025-09-22T14:37:05","date_gmt":"2025-09-22T12:37:05","guid":{"rendered":"https:\/\/www.esptcongress.org\/?page_id=3925"},"modified":"2025-09-22T14:37:05","modified_gmt":"2025-09-22T12:37:05","slug":"hertz-daniel","status":"publish","type":"page","link":"https:\/\/www.esptcongress.org\/index.php\/hertz-daniel\/","title":{"rendered":"Hertz Daniel"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column width=&#8221;1\/4&#8243;]<style type=\"text\/css\" data-type=\"the7_shortcodes-inline-css\">.shortcode-single-image-wrap.shortcode-single-image-ccd937470ab375f58c0f6cc43fb1e36f.enable-bg-rollover .rollover i,\n.shortcode-single-image-wrap.shortcode-single-image-ccd937470ab375f58c0f6cc43fb1e36f.enable-bg-rollover .rollover-video i {\n  background: -webkit-linear-gradient();\n  background: linear-gradient();\n}\n.shortcode-single-image-wrap.shortcode-single-image-ccd937470ab375f58c0f6cc43fb1e36f .rollover-icon {\n  font-size: 32px;\n  color: #ffffff;\n  min-width: 44px;\n  min-height: 44px;\n  line-height: 44px;\n  border-radius: 100px;\n  border-style: solid;\n  border-width: 0px;\n}\n.dt-icon-bg-on.shortcode-single-image-wrap.shortcode-single-image-ccd937470ab375f58c0f6cc43fb1e36f .rollover-icon {\n  background: rgba(255,255,255,0.3);\n  box-shadow: none;\n}<\/style><div class=\"shortcode-single-image-wrap shortcode-single-image-ccd937470ab375f58c0f6cc43fb1e36f alignnone  vc_custom_1758544552350 enable-bg-rollover dt-icon-bg-off\" ><div class=\"shortcode-single-image\"><div class=\"fancy-media-wrap  layzr-bg\" style=\"\"><img fetchpriority=\"high\" decoding=\"async\" class=\"preload-me lazy-load aspect\" src=\"data:image\/svg+xml,%3Csvg%20xmlns%3D&#39;http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg&#39;%20viewBox%3D&#39;0%200%20500%20500&#39;%2F%3E\" data-src=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hertz_foto-scaled-500x500.jpg\" data-srcset=\"https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hertz_foto-scaled-500x500.jpg 500w, https:\/\/www.esptcongress.org\/wp-content\/uploads\/2025\/09\/Hertz_foto-scaled-1000x1000.jpg 1000w\" loading=\"eager\" sizes=\"(max-width: 500px) 100vw, 500px\" width=\"500\" height=\"500\"  data-dt-location=\"https:\/\/www.esptcongress.org\/index.php\/speakers\/hertz_foto\/\" style=\"--ratio: 500 \/ 500;\" alt=\"\" \/><\/div><\/div><\/div><div class=\"standard-arrow list-divider bullet-top\"><ul>\n<li>Dr. Hertz Daniel<\/li>\n<\/ul>\n<\/div>[\/vc_column][vc_column width=&#8221;3\/4&#8243;]<div id=\"ultimate-heading-592869f2fa299264b\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-592869f2fa299264b uvc-9767 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-592869f2fa299264b h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;\">CV<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-592869f2fa299264b .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Dan Hertz is an Associate Professor at the University of Michigan College of Pharmacy.<\/p>\n<p>He received his PharmD from Rutgers University and PhD from University of North Carolina under Dr. Howard McLeod. Dr. Hertz\u2019s research focuses on developing individualized treatment strategies for patients with cancer and translating them into clinical practice.<\/p>\n<p>He has particular interests in biomarkers of taxane-induced neuropathy and DPYD testing to prevent severe fluoropyrimidine toxicity, including his role as a medical advisor to Advocates for Universal DPD\/DPYD Testing (AUDT).<\/div><\/div><div id=\"ultimate-heading-445269f2fa2992688\" class=\"uvc-heading ult-adjust-bottom-margin ultimate-heading-445269f2fa2992688 uvc-9040 color-title accent-title-color uvc-heading-default-font-sizes\" data-hspacer=\"no_spacer\"  data-halign=\"left\" style=\"text-align:left\"><div class=\"uvc-heading-spacer no_spacer\" style=\"top\"><\/div><div class=\"uvc-main-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-445269f2fa2992688 h2'  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}' ><h2 style=\"--font-weight:theme;margin-top:50px;\">ABSTRACT<\/h2><\/div><div class=\"uvc-sub-heading ult-responsive\"  data-ultimate-target='.uvc-heading.ultimate-heading-445269f2fa2992688 .uvc-sub-heading '  data-responsive-json-new='{\"font-size\":\"\",\"line-height\":\"\"}'  style=\"font-weight:normal;\">Fluoropyrimidines such as 5-fluorouracil and capecitabine are widely used in cancer treatment but carry a significant risk of severe, sometimes fatal toxicity in patients with reduced dihydropyrimidine dehydrogenase (DPD) activity due to inherited DPYD genetic variants.<\/p>\n<p>This presentation will explore the clinical implications of DPYD variation and its impact on fluoropyrimidine safety. Despite evidence of clinical utility for pre-treatment DPYD testing, adoption in the U.S. remains limited. I will discuss the key barriers to implementation, including evidentiary, logistical, and educational challenges. The talk will also review current guidance from major U.S. professional organizations\u2014specifically ASCO and NCCN\u2014highlighting how their recommendations on DPYD testing have evolved.<\/p>\n<p>In addition, I will examine the FDA\u2019s stance on DPYD testing, including labeling language and dosing considerations. By comparing these perspectives, the presentation aims to clarify the current regulatory and guideline landscape, identify gaps, and suggest opportunities to improve the safe use of fluoropyrimidines through DPYD testing and personalized dosing.<\/div><\/div>[\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column width=&#8221;1\/4&#8243;][\/vc_column][vc_column width=&#8221;3\/4&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3925","page","type-page","status-publish","hentry","description-off"],"_links":{"self":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/comments?post=3925"}],"version-history":[{"count":2,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3925\/revisions"}],"predecessor-version":[{"id":3927,"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/pages\/3925\/revisions\/3927"}],"wp:attachment":[{"href":"https:\/\/www.esptcongress.org\/index.php\/wp-json\/wp\/v2\/media?parent=3925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}